Research programme: Fc receptor modulators - InKine Pharmaceuticals

Drug Profile

Research programme: Fc receptor modulators - InKine Pharmaceuticals

Alternative Names: CBP 2011 series - InKine

Latest Information Update: 20 Jul 2009

Price : $50

At a glance

  • Originator InKine Pharmaceutical
  • Class
  • Mechanism of Action Fc receptor modulators; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Autoimmune haemolytic anaemia; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 03 Oct 2005 InKine Pharmaceutical has been acquired by Salix Pharmaceuticals
  • 20 May 2003 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
  • 20 May 2003 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top